Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25598176 | 0.89 | SMN1; SMN2 (0.54) | MAPTSMN1; SMN2GLAKDM4ELMNA | |
| SCHEMBL25599129 | 0.89 | SMN1; SMN2 (0.43) | MAPTSMN1; SMN2GLAKDM4EALDH1A1 | |
| SCHEMBL25599154 | 0.87 | F13A1 (0.44) | MAPTSMN1; SMN2GLAKDM4EALDH1A1 | |
| SCHEMBL25681675 | 0.86 | SMN1; SMN2 (0.42) | MAPTSMN1; SMN2GLAKDM4EALDH1A1 | |
| SCHEMBL25681606 | 0.83 | SMN1; SMN2 (0.43) | MAPTSMN1; SMN2GLAKDM4EALDH1A1 | |
| SCHEMBL25599089 | 0.83 | SMN1; SMN2 (0.43) | MAPTSMN1; SMN2GLAKDM4EALDH1A1 | |
| SCHEMBL25599228 | 0.81 | UCHL3 (0.40) | HDAC6 | |
| SCHEMBL25681648 | 0.79 | SMN1; SMN2 (0.41) | MAPTSMN1; SMN2GLAKDM4EALDH1A1 | |
| SCHEMBL25221183 | 0.78 | CCNK (0.44) | MAPTSMN1; SMN2LMNAKMT2ANPSR1 | |
| SCHEMBL30464385 | 0.78 | CCNK (0.44) | MAPTSMN1; SMN2LMNAKMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | MAPT 1673/4885SMN1; SMN2 2951/4885GLA 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.